▲
STOCKUPSIDE.IO
Analyst Price Target Intelligence
← Full Rankings
← Back to rankings
Ranked #4007 by analyst upside · 2026-11-14
DGX
Quest Diagnostics Incorporated
Healthcare · Market Cap $29B · P/E 25.9x
ANALYST PRICE TARGET
-0.9%
implied upside to consensus target
Current Price $259.6
Consensus Target $257.27
Bull Target $279.0
Bear Target $235.0
Analysts Covering 15
ANALYST CONSENSUS - BUY
Strong Buy
2
Buy
6
Hold
7
Sell
0
52-Week Low $171.18
52-Week High $262.0
YTD Return +51.9%
FUNDAMENTALS
Market Cap $29B
P/E Ratio (TTM) 25.9x
Forward P/E 21.7x
EPS (TTM) $10.04
PEG Ratio 1.69
Dividend Yield 1.32%
Revenue (TTM) $11.8B
Profit Margin 9.5%
52-WEEK RANGE
52-Week Low $171.18
52-Week High $262.0
Current Price $259.6
Bear Target $235.0
Bull Target $279.0
● Now $259.6 ● Target $257.27
TRADING DATA
Avg Volume 1.0M
YTD Return +51.9%
Analyst Count 15
Consensus Buy
Upside to Target -0.9%
Last Updated 2026-11-14

ANALYST SUMMARY

Quest Diagnostics Incorporated (DGX) is currently trading at $259.6 with a Wall Street consensus price target of $257.27, which is 0.9% below the current price over the next 12 months. 15 analysts currently cover DGX, with a consensus rating of Buy - 53% of analysts rate the stock a Buy or Strong Buy. The most bullish analyst has a price target of $279.0, while the most cautious has a target of $235.0.

DGX operates in the Healthcare sector with a market capitalisation of $29B. The stock is up 51.9% year-to-date and is currently trading near the upper end of its 52-week range of $171.18 – $262.0.

SIMILAR STOCKS

Other Healthcare stocks with comparable size and valuation.

RECENT ANALYST CALLS

Upgrade/downgrade history for DGX, with each firm's 90-day track record across all stocks we track. See full firm rankings →

Barclays - Reiterated
Overweight → Overweight 2026-10-07 Building track record
Truist Securities - Reiterated
Hold → Hold 2026-09-21 Building track record
UBS - Reiterated
Neutral → Neutral 2026-09-08 33% win rate (6 calls)
JP Morgan - Reiterated
Neutral → Neutral 2026-07-28 43% win rate (7 calls)
UBS - Reiterated
Neutral → Neutral 2026-07-25 33% win rate (6 calls)
Mizuho - Reiterated
Outperform → Outperform 2026-07-24 Building track record
Truist Securities - Reiterated
Hold → Hold 2026-07-24 Building track record
Barclays - Reiterated
Overweight → Overweight 2026-07-24 Building track record
HISTORICAL SNAPSHOT

Point-in-time data from StockUpside's daily snapshots. Tracks price, analyst target, upside %, consensus, and analyst count.

Loading…
ANALYST CONVICTION SCORE
55
out of 100
Coverage depth
21/30
Consensus clarity
27/30
Vote unanimity
5/25
Rating stability
2/15

Measures analyst agreement, not fundamental quality. A high score means analysts broadly agree on this call - not that the stock will go up.

See 4,000+ stocks ranked by analyst upside

StockUpside.io tracks analyst consensus price targets across thousands of US-listed stocks, updated every day. The full ranked list is available with a Pro subscription.

View Full Rankings →